Answers are grounded in this paper and cite their sources.
These initiatives continue to accelerate drug development for children with AML and ultimately improve clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Pearson et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: